What are the as‑needed medication options for breakthrough anxiety or panic attacks that do not involve benzodiazepines?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

PRN Medication Options for Breakthrough Anxiety or Panic Attacks (Non-Benzodiazepine)

For breakthrough anxiety or panic attacks when benzodiazepines are not an option, hydroxyzine (25-50 mg PRN) is the most practical first-line choice, followed by propranolol (10-40 mg PRN) or atenolol (25-50 mg PRN) for somatic anxiety symptoms, with low-dose quetiapine (25-50 mg PRN) reserved as a third-line option despite limited PRN-specific evidence.

Algorithmic Approach to PRN Non-Benzodiazepine Selection

First-Line: Hydroxyzine

  • Dosing: 25-50 mg orally PRN, up to 3-4 times daily 1
  • Onset: 15-30 minutes
  • Best for: Generalized anxiety symptoms, patients with substance use concerns, those requiring non-controlled substances
  • Cautions: Sedation, anticholinergic effects (dry mouth, confusion in elderly), QTc prolongation at higher doses
  • Advantage: FDA-approved for anxiety, non-addictive, rapid onset

Second-Line: Beta-Blockers

Propranolol (traditional choice):

  • Dosing: 10-40 mg PRN, 30-60 minutes before anticipated anxiety-provoking situations 2
  • Best for: Performance anxiety, panic attacks with prominent somatic symptoms (palpitations, tremor, sweating)
  • Cautions: Avoid in asthma, bradycardia, hypotension, heart block
  • Evidence: Established use for panic disorder and performance anxiety 2

Atenolol (emerging alternative):

  • Dosing: 25-50 mg PRN
  • Best for: Same indications as propranolol but may be better tolerated
  • Evidence: Preliminary data shows 86% of patients reported positive effects for anxiety symptoms, with 100% of patients who tried both preferring atenolol over propranolol 3
  • Advantage: Longer half-life allows once-daily dosing, cardioselective (safer in mild reactive airway disease)

Third-Line: Low-Dose Atypical Antipsychotics

Quetiapine:

  • Dosing: 25-50 mg PRN (significantly lower than typical antipsychotic dosing) 4, 5
  • Best for: Severe breakthrough anxiety unresponsive to above options, patients with comorbid agitation
  • Cautions: Sedation, metabolic effects with chronic use, extrapyramidal symptoms (rare at low doses), monitor for diabetes/weight gain
  • Evidence: Supported for generalized anxiety disorder 5, used PRN for breakthrough nausea/agitation in other contexts 4
  • Important caveat: Most evidence is for scheduled dosing, not PRN use; reserve for refractory cases

Olanzapine:

  • Dosing: 2.5-5 mg PRN 4, 6
  • Best for: Acute severe agitation with anxiety (particularly in elderly or medically complex patients)
  • Cautions: Similar to quetiapine; do NOT combine with parenteral benzodiazepines within 2 hours due to respiratory depression risk 6

Alternative Considerations

Antihistamines (Beyond Hydroxyzine)

  • Diphenhydramine: 25-50 mg PRN, but more sedating and anticholinergic than hydroxyzine; not recommended as first choice 1

Buspirone

  • NOT recommended for PRN use: Requires 2-4 weeks of regular dosing to become effective 1, 5
  • Only effective with chronic scheduled administration

Gabapentin/Pregabalin

  • Limited PRN evidence: Primarily studied for scheduled dosing in generalized anxiety disorder 5, 7
  • Gabapentin: May help anxiety-related insomnia when dosed at bedtime 8
  • Concern: Increasing misuse potential; requires careful patient selection 8

Critical Clinical Pitfalls

  1. Avoid antihistamine/analgesic OTC combinations for chronic anxiety management—lack efficacy and safety data 9

  2. Do not use barbiturates or chloral hydrate—outdated, dangerous, not recommended 1

  3. Paradoxical reactions: Approximately 10% of patients experience paradoxical agitation with benzodiazepines 1; this can also rarely occur with antihistamines

  4. Elderly patients: Start with half doses of any agent; hydroxyzine and beta-blockers require particular caution due to anticholinergic effects and orthostatic hypotension respectively 6

  5. Tolerance development: Even non-benzodiazepine PRN medications can lead to psychological dependence on "rescue" medications; integrate with cognitive-behavioral therapy when possible 10

  6. Beta-blocker contraindications: Screen for asthma, COPD, heart block, bradycardia, and hypotension before prescribing 2

Monitoring and Follow-Up

  • Reassess within 2-4 weeks of initiating any PRN medication to evaluate:

    • Frequency of use (if using daily, consider scheduled maintenance therapy)
    • Effectiveness for target symptoms
    • Adverse effects
    • Need for underlying maintenance treatment with SSRIs/SNRIs 11, 7
  • PRN medications are temporizing measures: Most patients with recurrent panic attacks or breakthrough anxiety require scheduled maintenance pharmacotherapy (SSRIs/SNRIs as first-line) combined with cognitive-behavioral therapy 7, 12, 13

  • Document specific indications for PRN use and review daily in acute settings 6

References

Guideline

antiemesis.

Journal of the National Comprehensive Cancer Network : JNCCN, 2012

Research

Non-Antidepressant Treatment of Generalized Anxiety Disorder.

Current clinical pharmacology, 2015

Research

Current and Novel Psychopharmacological Drugs for Anxiety Disorders.

Advances in experimental medicine and biology, 2020

Guideline

clinical guideline for the evaluation and management of chronic insomnia in adults.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2008

Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.